1. Home
  2. CISS vs PRFX Comparison

CISS vs PRFX Comparison

Compare CISS & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo C3is Inc.

CISS

C3is Inc.

N/A

Current Price

$0.54

Market Cap

2.7M

ML Signal

N/A

Logo PainReform Ltd.

PRFX

PainReform Ltd.

HOLD

Current Price

$0.72

Market Cap

3.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CISS
PRFX
Founded
2022
2007
Country
Greece
Israel
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7M
3.1M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
CISS
PRFX
Price
$0.54
$0.72
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 428.5K
26.1K
Earning Date
11-17-2026
09-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.82
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.06
$0.58
52 Week High
$6.06
$5.39

Technical Indicators

Market Signals
Indicator
CISS
PRFX
Relative Strength Index (RSI) 33.75 39.90
Support Level $0.41 $0.69
Resistance Level $0.61 $1.28
Average True Range (ATR) 0.07 0.05
MACD 0.01 0.00
Stochastic Oscillator 25.47 31.01

Price Performance

Historical Comparison
CISS
PRFX

About CISS C3is Inc.

C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including national and private industrial users, commodity producers, and traders. The company owns and operates a fleet of two dry bulk carriers that transport bulk commodities such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers.

About PRFX PainReform Ltd.

PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.

Share on Social Networks: